Cremolini C, Antoniotti C, Rossini D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(4):497–507. https://doi.org/10.1016/S1470-2045(19)30862-9

Article  CAS  PubMed  Google Scholar 

Janssen QP, van Dam JL, Bonsing BA et al (2021) Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21(1):300. https://doi.org/10.1186/s12885-021-08031-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Liang H, Li Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22(8):1081–1092. https://doi.org/10.1016/S1470-2045(21)00297-7

Article  CAS  PubMed  Google Scholar 

Soveri LM, Lamminmäki A, Hänninen UA et al (2019) Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 58(4):398–406. https://doi.org/10.1080/0284186X.2018.1556804

Article  CAS  PubMed  Google Scholar 

de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947. https://doi.org/10.1200/JCO.2000.18.16.2938

Article  PubMed  Google Scholar 

Yoshino T, Oki E, Misumi T et al (2022) Final analysis of 3 versus 6 months of adjuvant oxaliplatin and Fluoropyrimidine-Based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial. J Clin Oncol 40(29):3419–3429. https://doi.org/10.1200/JCO.21.02628

Article  CAS  PubMed  Google Scholar 

Wei G, Gu Z, Gu J et al (2021) Platinum accumulation in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst 26(1):35–42. https://doi.org/10.1111/jns.12432

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgess J, Ferdousi M, Gosal D et al (2021) Chemotherapy-Induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 9(2):385–450. https://doi.org/10.1007/s40487-021-00168-y

Article  PubMed  PubMed Central  Google Scholar 

Tsukushi Y, Kobuchi S, Ito Y, Sakaeda T (2024) Pharmacokinetic-toxicodynamic modeling to elucidate the involvement of dorsal root ganglion neuron in Oxaliplatin-induced peripheral neuropathy. Anticancer Res 44(2):575–584. https://doi.org/10.21873/anticanres.16846

Article  PubMed  Google Scholar 

Ko M, Oh JM, Kim IW (2023) Drug repositioning prediction for psoriasis using the adverse event reporting database. Front Med (Lausanne) 10:1159453. https://doi.org/10.3389/fmed.2023.1159453

Article  PubMed  Google Scholar 

Liu Y, Liu Y, Fan R et al (2023) Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis. Eur J Med Res 28(1):95. https://doi.org/10.1186/s40001-023-01048-z

Article  PubMed  PubMed Central  Google Scholar 

Wakai E, Suzumura Y, Ikemura K et al (2020) An integrated in Silico and in vivo approach to identify protective effects of palonosetron in Cisplatin-Induced nephrotoxicity. Pharmaceuticals (Basel) 13(12):480. https://doi.org/10.3390/ph13120480

Article  CAS  PubMed  Google Scholar 

Kobayashi A, Ikemura K, Wakai E et al (2023) Proton pump inhibitors ameliorate Oxaliplatin-induced peripheral neuropathy: retrospective analysis of two Real-world clinical databases. Anticancer Res 43(12):5613–5620. https://doi.org/10.21873/anticanres.16764

Article  CAS  PubMed  Google Scholar 

Begg M, Tarhuni M, N Fotso M et al (2023) Comparing the safety and efficacy of proton pump inhibitors and Histamine-2 receptor antagonists in the management of patients with peptic ulcer disease: A systematic review. Cureus 15(8):e44341. https://doi.org/10.7759/cureus.44341

Article  PubMed  PubMed Central  Google Scholar 

Simadibrata DM, Lesmana E, Pratama MIA et al (2024) Vonoprazan vs. Proton pump inhibitors for treatment and prevention of gastric and/or duodenal ulcers: A systematic review with Meta-Analysis. Dig Dis Sci 69(10):3863–3874. https://doi.org/10.1007/s10620-024-08593-5

Article  CAS  PubMed  Google Scholar 

Nies AT, Hofmann U, Resch C et al (2011) Proton pump inhibitors inhibit Metformin uptake by organic cation transporters (OCTs). PLoS ONE 6(7):e22163. https://doi.org/10.1371/journal.pone.0022163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pochini L, Scalise M, Indiveri C (2009) Inactivation by Omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. Chem Biol Interact 179(2–3):394–401. https://doi.org/10.1016/j.cbi.2008.10.052

Article  CAS  PubMed  Google Scholar 

Ito Y, Kobuchi S, Takesada W, Takahashi C (2019) Assessment of Oxaliplatin-induced chronic neuropathy and anticancer efficacy through Pharmacokinetic and toxicodynamic evaluation of a rat model of colorectal cancer. Anticancer Res 39(8):4207–4213. https://doi.org/10.21873/anticanres.13581

Article  CAS  PubMed  Google Scholar 

Liu W, Liu G, Liu J (2019) Effects of Astragaloside IV on the pharmacokinetics of Omeprazole in rats. Pharm Biol 57(1):449–452. https://doi.org/10.1080/13880209.2019.1636828

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Smet J, Boussery K, De Cock P et al (2010) A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of Omeprazole and Lansoprazole in human plasma in support of a Pharmacokinetic Omeprazole study in children. J Sep Sci 33(6–7):939–947. https://doi.org/10.1002/jssc.200900590

Article  CAS  PubMed  Google Scholar 

Utsumi D, Matsumoto K, Amagase K et al (2016) 5-HT3 receptors promote colonic inflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis. Br J Pharmacol 173(11):1835–1849. https://doi.org/10.1111/bph.13482

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes JH, Keizer RJ (2021) A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori bayesian Estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol 10(10):1150–1160. https://doi.org/10.1002/psp4.12684

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mine K, Kawashiri T, Inoue M et al (2022) Omeprazole suppresses Oxaliplatin-Induced peripheral neuropathy in a rodent model and clinical database. Int J Mol Sci 23(16):8859. https://doi.org/10.3390/ijms23168859

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheu ML, Pan LY, Sheehan J et al (2022) Modulation of Aryl hydrocarbon receptor expression alleviated neuropathic pain in a chronic constriction nerve injury animal model. Int J Mol Sci 23(19):11255. https://doi.org/10.3390/ijms231911255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujita S, Hirota T, Sakiyama R et al (2019) Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. J Neurochem 148(3):373–385. https://doi.org/10.1111/jnc.14607

Article  CAS  PubMed  Google Scholar 

Juricek L, Coumoul X (2018) The Aryl hydrocarbon receptor and the nervous system. Int J Mol Sci 19(9):2504. https://doi.org/10.3390/ijms19092504

Article  CAS  PubMed  PubMed Central  Google Scholar